Singapore-founded healthtech company AIGP Health has expanded its Southeast Asian presence by launching its Anzu clinical AI platform in Thailand. This move, in partnership with Borderless Healthcare Group (BHG), marks AIGP Health’s entry into its third market, following successful operations in Singapore and Australia. The Anzu platform is designed to assist clinicians by providing patient information and clinical context throughout consultations, whilst maintaining clinical judgement with healthcare professionals.
The launch in Thailand is part of AIGP Health’s broader regional growth strategy, which includes potential expansions into Malaysia and Indonesia. The company aims to integrate its AI technology into various healthcare settings, such as hospitals, clinics, and wellness centres, to support clinicians in making informed decisions within limited consultation times.
Sheetal Nanwani Doshi, Co-Founder and Chief Growth Officer of AIGP Health, highlighted the platform’s unique selling proposition: “Anzu addresses a complete new category called Clinical Risk… Our USP is our deep clinical workflows built to be able to address these factors therapy wise.”
The Anzu platform, which includes tools like Anzu Dr Assist and Anzu Preclerk, is designed to work alongside existing healthcare technology infrastructures. It has already supported over 3,000 patients across Singapore and Australia. In Thailand, the platform is being deployed at the Global Institute of Aesthetics in Bangkok, serving as a flagship site for its integration into real-world care environments.
As AIGP Health continues its expansion, the company aims to demonstrate how clinical AI can be adapted to diverse healthcare environments, ensuring that doctors and patients remain at the centre of care.
